Cognition Therapeutics (CGTX) Expected to Announce Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Cognition Therapeutics to announce earnings of ($0.07) per share and revenue of $5.30 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. On average, analysts expect Cognition Therapeutics to post ($0.30) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

Cognition Therapeutics Stock Down 1.4%

Shares of CGTX stock opened at $0.70 on Wednesday. The business’s fifty day moving average price is $0.90 and its 200 day moving average price is $1.06. Cognition Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.82.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, September 21st. Wall Street Zen lowered Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reissued a “buy” rating on shares of Cognition Therapeutics in a research note on Monday, October 5th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $3.33.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.